Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC
Conditions
NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Trial Timeline
Oct 12, 2022 → Nov 1, 2027
NCT ID
NCT05546268About Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359
Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 + Oral MRT-2359 is a phase 1/2 stage product being developed by Monte Rosa Therapeutics for NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT05546268. Target conditions include NSCLC, SCLC, High Grade Neuroendocrine Cancer.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
9
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05546268 | Phase 1/2 | Active |
Competing Products
20 competing products in NSCLC